Helleday Laboratory
News
Here you can read our latest research, awards and insights.
Meny
Here you can read our latest research, awards and insights.
The Wallenberg Scholars program aims to provide leading researchers in Sweden with grants for free research. Following a comprehensive international peer review, the Foundation has chosen to fund 118 researchers for five years, providing up to SEK 18 million each for researchers in theoretical subjects and up to SEK 20 million each for researchers in experimental subjects. Of the 29 medical researchers awarded this year’s Scholar grants, 19 are active at Karolinska Institutet. Thomas Helleday is one of the awardees, receiving SEK 20 million during 5 years.
As a Wallenberg Scholar, Professor Helleday hopes to develop a new type of therapeutic method for treating diseases and ageing. His aim is to produce more efficacious drugs through the development of new, biochemical treatment methods.
Read more here
Maurice Michel, Associate Professor at the Helleday laboratory is the winner of the Nature Eppendorf award for 2023.
According to the award judges, Maurice Michel has showed that binding of a small molecule to the active site of a DNA repair enzyme not only increases its activity but also prompts it to carry out a reaction not found in the free protein, leading to enhanced DNA repair after oxidative damage. Currently Maurice Michel is focusing on broadening this technology by investigating other enzymes and biomedical reaction pathways, with the hope of finding new strategies for rerouting or reducing oxidative DNA damage according to individual needs.
The Eppendorf Award for Young European Investigators was first established in 1995. It acknowledges outstanding contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts. The Award is presented in partnership with Nature.
Read more about the Nature Eppendorf Award here
We are extremely proud to publish in Nature Metabolism the detailed mechanism on how our MTHFD1/2 inhibitors work and why they specifically kill cancer cells. This constitutes a new major attack on cancer and we are excited to see how it works in the clinic.
Read the full article here